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Available online 17 September 2016Background: Diabetic nephropathy is the most common cause of end stage renal failure. We assessed the safety,
tolerability, and explored therapeutic effects of adult allogeneic bone-marrow derived mesenchymal precursor
cells (MPC) in patients with moderate to severe diabetic nephropathy.
Methods:Multicenter, randomized, double-blind, dose-escalating, sequential, placebo-controlled trial assessing a
single intravenous (IV) infusion of allogeneic MPC (United States adopted name: rexlemestrocel-L) 150 × 106
(n = 10), 300 × 106 (n = 10) or placebo (n = 10) in adults with diabetic nephropathy with an estimated glo-
merular ﬁltration rate (eGFR) 20–50 ml/min/1.73 m2. Thirty patients at three Australian centers were enrolled
between July 2013 and June 2014 and randomized 2:1, in two sequential dose cohorts, to receive
rexlemestrocel-L or placebo. Study durationwas 60weeks. Primary endpoint was safety and tolerability. Primary
exploratory efﬁcacy endpointwas change frombaseline in eGFR and directlymeasuredGFRby 99Tc-DTPA plasma
clearance (mGFR) at 12 weeks post-infusion. The trial was registered on ClinicalTrials.gov (NCT01843387).
Findings: All patients completed the study and were included in analyses applied to the intention to treat popu-
lation. There were no acute adverse events (AEs) associated with infusion and no treatment-related AEs or seri-
ous AEs were deemed treatment-related by investigators. No patients developed persistent donor speciﬁc anti-
HLA antibodies. Relative to placebo, a single IV rexlemestrocel-L infusion showed trends of stabilizing or improv-
ing eGFR andmGFR atweek 12. The adjusted least squaresmean (LSM±SE) differences fromplacebo in changes
from baseline at 12 weeks in the rexlemestrocel-L groups were 4.4 ± 2.16 and 1.6 ± 2.15 ml/min/1.73 m2 for
eGFR and 4.1 ± 2.75 and 3.9 ± 2.75 for mGFR for the 150 × 106 and 300 × 106 cell groups, respectively.
Interpretation: This study demonstrates the safety of rexlemestrocel-L in diabetic nephropathy with suggestive
effects on renal function to be conﬁrmed in larger, appropriately powered trials.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Diabetes is the most common underlying cause of chronic kidney
disease leading to renal failure, accounting for about 40–50% of cases
(Tuttle et al., 2014). Although inhibition of the renin-angiotensin aldo-
sterone system can slow progression of diabetic kidney disease, the re-
sidual risk of progression to end stage renal failure is high (Lewis et al.,
2001; Brenner et al., 2001). Appreciation of the multiple pathways by
which progressive kidney injury occurs has led to a search for novel
therapeutic approaches to slow, halt or reverse progression of renal
disease in type 2 diabetic patients. Research has implicated inﬂamma-
tion as one contributing factor in the pathophysiology of diabeticckham).
. This is an open access article undernephropathy (Wada & Makino, 2013; Navarro-Gonzalez &
Mora-Fernandez, 2011; Lim & Tesch, 2012). The anti-inﬂammatory
properties of adult, bone-marrow derived mesenchymal lineage cells
may have beneﬁcial effects in diabetic nephropathy, as suggested by ob-
served effects on renal function and histology in animal models of
chronic kidney disease (Prockop & Oh, 2012; Singer & Caplan, 2011;
Cantaluppi et al., 2013). Other properties such as tropism for damaged
tissues and secretion of a broad range of bioactive molecules with sub-
sequent paracrine effects contribute to the effects on renal function
and histopathology in preclinical chronic and acute kidney injury
models (Papazova et al., 2015; Meirelles Lda et al., 2009; Hickson
et al., 2016). In addition, the capacity of this cell type to reprogrammac-
rophages from a proinﬂammatory M1 phenotype to the alternatively
activated or anti-inﬂammatory M2 phenotype may also promote tissue
repair (Maggini et al., 2010; Kim & Hematti, 2009).the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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MPC and to explore its effects on renal function in patients withmoder-
ate to severe diabetic nephropathy as assessed by glomerular ﬁltration
ratemeasured directly by 99Tc DTPA plasma clearance (mGFR) and esti-
mated (eGFR) from serum creatinine using the Modiﬁcation of Diet in
Renal Disease (MDRD) equation (Levey et al., 1999).
2. Methods
2.1. Study Population
The study populationwasmale and female patients ≥45 and ≤85 years
old with type 2 diabetes and advanced diabetic nephropathy (e.g. eGFR
20–50 ml/min/1.73 m2) (Kidney Disease: Improving Global Outcomes
(KDIGO) CKDWork Group, 2013) who were receiving a stable, standard
of care therapeutic regimen of the maximum tolerated recommended
dose of an angiotensin converting enzyme inhibitor (ACEi) or a angioten-
sin 2 receptor blocker (ARB) for at least 3 months prior to screening.
Because at the time that this study was initiated the potential for
allosensitization from systemic infusion of cells from unrelated donors
was unknown, only patients who, in the opinion of the investigator
and, in accordance with the current consensus recommendations in
Australia would be unlikely candidates for kidney transplant were in-
cluded. Women of childbearing potential who were surgically sterile
or agreed to use contraception were eligible to participate in the
study. Exclusion criteria included: New York Heart Association Class III
or IV heart failure and myocardial infarction or stroke within 6 months
of screening. Complete eligibility criteria are provided in the Supple-
mental Study Protocol.
2.2. Study Procedures
This multicenter, randomized, double-blind, placebo-controlled, se-
quential, dose-escalation study assessed the safety, tolerability, and ex-
ploratory efﬁcacy of a single intravenous infusion of rexlemestrocel-L.
The studywas conducted at 4 centers in Australia with patients enrolled
at 3 clinical sites and all infusions conducted at the same phase 1 unit.
The study consisted of an initial screening period not to exceed
4weeks and a 60week double-blind treatment and follow-up period in-
cluding safety and renal function assessments, immune system re-
sponses and clinical laboratory parameters. The study, conducted
between July 2013 and August 2015, was approved by the ethics com-
mittees of the participating centers and conducted in accordance with
the principles of the Declaration of Helsinki and International Confer-
ence on Harmonization - Good Clinical Practice guidelines. All partici-
pants provided written informed consent. The trial was registered on
ClinicalTrials.gov (NCT01843387).
2.3. Randomization
An Interactive Voice Response System/Interactive Web Response
System (IVRS/IWRS) was accessed to randomize eligible patients. Pa-
tients were randomized to receive one of two rexlemestrocel-L doses
or placebo in a 2:1 ratio using a sequential, escalating dose cohort para-
digm: cohort 1: 150 × 106 [n = 10] or placebo [n = 5]; and cohort 2:
300 × 106 [n = 10] or placebo [n = 5]. The randomization within
each cohort was balanced by permuted block stratiﬁcation, based on
screening eGFR ≤30 ml/min/1.73 m2 or N30 ml/min/1.73 m2.
2.4. Study Procedures
Treatmentwas administered by IV infusion onDay 0 following base-
line assessments. Patients, investigators, and the sponsor were blinded
to treatment allocation through the entire 60-week study. The investi-
gational product is comprised of a STRO-3 immuno-selected, culture-
expanded, immature subfraction of adult, bone marrow–derivedmononuclear cells from healthy paid adult donors (U.S. adopted name
rexlemestrocel-L) (Simmons & Torok-Storb, 1991; Gronthos et al.,
2007; Skyler et al., 2015). Full details of rexlemestrocel-L source,
donor screening, preparation, and investigational product administra-
tion are provided in the Supplementary Appendix. Importantly,
however, these cells do not express human leukocyte antigen (HLA)
Class II and CD80 and CD86 co-immunostimulatory molecules.
Rexlemestrocel-L or saline placebo were suspended in 100 ml normal
saline and infused with ﬁltration over 45 min. All infusions were pre-
pared by an unblinded pharmacist at the phase 1 unit who provided
to the blinded clinical staff visually identical infusion products com-
prised of rexlemestrocel-L or saline suspended in 100 ml normal saline.
Vital signs and oxygen saturation were monitored continuously during
and for 6 hour post-infusion. All patients remained on their background
medications and received standard of caremanagement throughout the
study.
2.5. Study Oversight
This study was sponsored by Mesoblast, Inc. and was designed by
the sponsorwith input from the authors and the contract research orga-
nization (CRO; Medpace, Inc., Cincinnati OH). The study database was
held by the CRO and employees of Medpace performed the statistical
analyses. All authors participated in manuscript preparation, made the
decision to submit the manuscript for publication, and vouch for the
completeness and accuracy of the data.
An independent Data Monitoring Committee (DMC) comprised of
independent physicianswith expertise in nephrology, diabetes, and car-
diology, and the conduct of clinical trials, and an independent biostatis-
tician ensured the safety of the patients enrolled in the study. The DMC
reviewed safety data when all patients in the ﬁrst dose cohort complet-
ed theWeek 1 visit and issued a certiﬁcate of non-objection to advance
to the higher dose cohort to the sponsor. Formal stopping rules were in
place for the DMC to hold enrollment or recommend termination the
study of any event of Common Terminology Criteria for Adverse Events
(CTCAE) (United States Department of Health and Human Services,
2010) grade 4 or higher pulmonary/upper respiratory toxicity occurring
at any time after study drug infusion or CTCAE grade 3 or higher im-
mune system toxicity occurring within 7 days of study drug infusion.
2.6. Outcomes
Safety was assessed by adverse events, laboratory measurements
(hematology, chemistry, and urinalysis), vital signs, 12-lead ECGs, phys-
ical examination ﬁndings, and review of antibody speciﬁcity testing for
anti-HLA Class I and Class II antibodies and anti-murine and anti-bovine
antibodies. Pre-speciﬁed safety parameters of special interest included
any adverse event reported during the infusion or the 6-hour post-
infusion period and any adverse events in the immune system or respi-
ratory system organ classes. GFR was estimated from serum creatinine
(eGFR) using the 4-variable Modiﬁcation of Diet in Renal Disease
(MDRD) equations at every visit and measured directly by 99Tc DTPA
plasma clearance (mGFR) at baseline and 12 weeks. Urinary albumin
and protein, urinary albumin: creatinine and urinary protein: creatinine
ratios, and creatinine clearance were assessed from a 24-h urine collec-
tion at baseline andweek 12. Selected biomarkersweremeasured at the
same timepoints.
2.7. Assay Procedures
Immune proﬁling consisted of Panel Reactive Antibodies (PRA) by
ﬂow cytometry to detect the presence of donor speciﬁc antibodies
(DSA) assessed on Day 0 and weeks 4, 12, 36 and 60. Assays were per-
formed using a Luminex platform by the Blood Center of Wisconsin.
Human leukocyte antigen (HLA) status was reported as negative if
Class I or Class II percent PRA (%PRA) of the total antigens tested was
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itive was deﬁned as %PRA N20%. Positive DSAwas identiﬁed when anti-
body speciﬁcities were directed to the MPC donor HLA antigens. IL-6
and TNF-a were measured by ELISA and hsCRP was determined by
nephelometry.2.8. Statistical Analyses
The primary objective of this study was to assess safety and tolera-
bility ofMPC therapy. Accordingly, therewas no formal hypothesis test-
ing or accompanying power analysis to indicate a sufﬁcient sample size
to identify signiﬁcant treatment differences in renal function outcomes
between rexlemestrocel-L and placebo. Efﬁcacy analyseswere primarily
descriptive and hypothesis generating. p-Values for selected efﬁcacy
analyses were generated for exploratory purposes.
Demographic and baseline characteristics were summarized for all
randomized patients by treatment group. Safety analyses were applied
to the safety population, deﬁned as all patients that received study
treatment and had at least one follow-up safety evaluation. All efﬁcacy
analyses were applied to the intent-to-treat (ITT) population, deﬁned
as all randomized patients who received study treatment and had at
least one evaluable post-baseline renal function assessment. In case of
missing data the last evaluable assessment was carried forward to the
endpoint (LOCF). The primary efﬁcacy variables were changes from
baseline in eGFR andmGFR at week 12. Treatment differences in efﬁca-
cy endpoints were obtained using an analysis of covariance model with
treatment and eGFR strata (≤30 or N30 ml/min/1.73 m2) as factors and
baseline value as covariate. The difference in least-squaresmeans (LSM)
and corresponding standard errors are presented. Sensitivity analysis
was applied to compare eGFR values derived using the MDRD equation
and the more recent, widely accepted Chronic Kidney Disease Epidemi-
ology Collaboration (CKD-EPI) equation (Levey et al., 2009). This and an
additional subgroup analysis are provided in the Supplemental Appen-
dix. Data were analyzed using SAS Version 9.1. The statistical analysis
plan for this study is available as a supplemental Statistical Analysis
Plan.Fig. 1. Disposition2.9. Role of the Funding Source
The studywas sponsored and funded byMesoblast, Inc. The sponsor
provided oversight to the contract research organization, Medpace, Inc.,
responsible for data collection, data review, statistical analysis and the
clinical study report. The sponsor had no role in the data collection or
analysis. The sponsor reviewed the manuscript before it was submitted
for publication but did not control the interpretation of the results or the
decision to submit the manuscript for publication. The corresponding
author had full access to all the data and had full responsibility for the
decision to submit the manuscript for publication.
3. Results
3.1. Study Participants
Thirty patients were enrolled at 3 centers in Melbourne, Australia
between July 2013 and June 2014. The disposition of patients is shown
in Fig. 1.
All randomized patients completed the study. Demographic and key
baseline characteristics are shown in Table 1.
3.2. Safety
All patients received the full infusion. No adverse events were re-
ported during infusion or the 6 hour post-infusion monitoring period.
Over the entire 60 week study period 7 (70%), 8 (80%) and 9 (90%) of
patients in the placebo and rexlemestrocel-L 150 × 106 and 300 × 106
groups experienced any adverse event (Table 2A). Adverse events
were generally mild to moderate intensity, resolved without sequelae
and none led to premature study discontinuation or were considered
to be treatment-related by the investigators (Table 2A). The most com-
monly reported TEAEs were edema peripheral (5 reported events),
lower respiratory tract infection (Wada & Makino, 2013), urinary tract
infection (Brenner et al., 2001), cataract (Brenner et al., 2001), and ane-
mia (Brenner et al., 2001) which were generally balanced acrossof patients.
Table 1
Demographic and baseline characteristics.
Parameter Placebo
(N = 10)
Rexlemestrocel-L
150 × 106
(N = 10)
300 × 106
(N = 10)
Gender, n (%) Male 8 (80.0%) 9 (90.0%) 7 (70.0%)
Female 2 (20.0%) 1 (10.0%) 3 (30.0%)
Age, years 74.8 ± 7.9a 70.5 ± 7.4 64.8 ± 10.1
Race, n (%) Caucasian 10 (100.0%) 9 (90.0%) 10 (100.0%)
Asian 0 (0.0%) 1 (10.0%) 0 (0.0%)
Height, cm 166.3 ± 8.7 172.3 ± 8.4 171.2 ± 10.4
Baseline weight, kg 83.5 ± 20.2 97.4 ± 21.8 101.3 ± 25.0
Body mass index, kg/m2 30.3 ± 6.4 32.7 ± 6.2 34.2 ± 5.9
Baseline eGFR (MDRD),
ml/min/1.73 m2
34.6 ± 9.22 35.7 ± 10.35 34.6 ± 12.38
≤30 ml/min/1.73 m2, n (%) 3 (30%) 3 (30%) 5 (50%)
N30 ml/min/1.73 m2, n (%) 7 (70%) 7 (70%) 5 (50%)
Baseline mGFR, ml/min/1.73 m2 34.6 (9.7) 37.4 (12.11) 35.4 (11.44)
Baseline HbA1c (%) 6.8 ± 1.3 7.5 ± 1.2 7.9 ± 2.1
b8%b 8 (80%) 5 (50%) 6 (60%)
≥8%b 2 (20%) 5 (50%) 4 (40%)
Albumin-creatinine ratio (ACR, mg/g) 408 ± 552 391 ± 787 404 ± 736
ACR b30 mg/g, n (%) 0 (0%) 0 (0%) 3 (30%)
ACR 30–300 mg/g, n (%) 6 (60%) 8 (80%) 4 (40%)
ACR N300 mg/g, n (%) 4 (40%) 2 (20%) 3 (30%)
CKD regimen, n (%)b
ACEi, n (%) 1 (10.0%) 3 (30.0%) 1 (10.0%)
ARB, n (%) 8 (80.0%) 7 (70.0%) 8 (80.0%)
a Values are Mean ± SD unless otherwise noted.
b One patient in the Placebo group was on a regimen of ACEi plus ARB therapy; one
patient in the 300 × 106 group had documented ACEi and ARB intolerance.
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events (SAEs) were reported by 2 (20%), 4 (40%), and 1 (10%) patients
in the placebo and rexlemestrocel-L 150× 106 and 300× 106 groups, re-
spectively (Table 2B). SAEs of diabetic foot ulcer/infection were report-
ed in 3 rexlemestrocel-L-treated patients (two in the 150 × 106 and one
in the 300 × 106 group). All of these patients had a history of diabetic
neuropathy and/or prior diabetic foot ulcer including a prior hallux am-
putation in one patient. Serious cardiac disorders were reported in 2Table 2
Safety.
Placebo
(N = 10)
Rexlemestrocel-L
150 × 106
(N = 10)
300 × 106
(N = 10)
A. Summary of Treatment-Emergent Adverse Events (TEAEs)a
Patients with any TEAEs 7 (70.0%) 8 (80.0%) 9 (90.0%)
Patients with any treatment-related TEAEsa 0 (0.0%) 0 (0.0%) 0 (0.0%)
TEAEs leading to discontinuation 0 (0.0%) 0 (0.0%) 0 (0.0%)
Patients with any serious TEAEs 2 (20.0%) 4 (40.0%) 1 (10.0%)
B. Listing of serious adverse events
Group Patient Serious adverse event
Placebo A Fall
Placebo B Acute myocardial infarction
Anemia
Asthma
Cardiac failure congestive
Cardiac failure congestive
Syncope
Upper gastrointestinal hemorrhage
150 × 106 C Gangrene
150 × 106 D Infected skin ulcer
150 × 106 E Atrial ﬁbrillation
Renal failure chronic
150 × 106 F Benign prostatic hyperplasia
300 × 106 G Diabetic ulcer
Diverticulitis
a Treatment-emergent adverse events are thosewith an onset during or after treatment
infusion.patients: one placebo-treated patient experienced acute myocardial in-
farction and two hospitalisations for congestive heart failure and one
patient in the rexlemestrocel-L 150 × 106 group was hospitalised for
atrial ﬁbrillation. No SAEswere judged by the investigators to be related
to treatment. No acute allergic or immunologic adverse events were re-
ported. AEs of dyspnea exertional, asthma, cough, pleural effusion, and
wheezingwere balanced across treatment groups and noneoccurred ei-
ther during or immediately after infusion or were deemed related to
treatment.
One active-treated patient developed antibodies speciﬁc to the
donor HLA (antibody speciﬁcity to donor antigen B40; mean ﬂuores-
cence intensity 530) at week 4 that were undetectable at week 12;
donor speciﬁc anti-HLA panel reactive antibodies (DSA) present at base-
line in one patient persisted throughout the entire studywith no associ-
ated adverse events; and one placebo-treated patient developed panel
reactive antibodies speciﬁc to the donor HLA at week 60 with antibody
speciﬁcity to donor antigen CW6 andmeanﬂuorescence intensity 4779.
The reason for an isolated observation of DSA in a placebo treated pa-
tient is unknown. Possible explanations for a non-exposed patient de-
veloping DSA include some sensitizing event such as a blood
transfusion, vaccination, infection or exposure to some other unidenti-
ﬁed antigen. Infection could upregulate the immune system resulting
in expression of these antibodies. This patient did not receive a transfu-
sion between week 36 and 60. There were no clinically signiﬁcant in-
creases in either Class I or Class II %PRA at any timepoint.
3.3. Exploratory Efﬁcacy
The primary exploratory efﬁcacy parameterwas the effect of a single
IV administration of rexlemestrocel-L on renal function over 12 weeks
as assessed by isotopically measured and estimated GFR based on
serum creatinine. Relative to placebo, the LSM (SE) change from base-
line in mGFR at week 12 (Fig. 2A) was 4.1 ± 2.75 for the 150 × 106
group (p = 0.15) and for the 3.9 ± 2.8 ml/min/1.73 m2 in the 300 ×
106 group (p = 0.17). The placebo-adjusted LSM change in eGFR at
week 12 (Fig. 2B) was 4.4 ± 2.2 (p= 0.05) and 1.6 ± 2.2 ml/min/1.73
m2 (p= 0.47) for the 150 × 106 and 300 × 106 groups, respectively.
Additional selected efﬁcacy parameters are shown in Table 3. There
were no effects of treatment on urinary albumin, protein, albumin-
creatinine, protein-creatinine ratios, creatinine clearance, lipid proﬁle,
HbA1c or blood pressure. There was a statistically signiﬁcant decrease
in the median IL-6 values for the 300 × 106 group compared to placebo
atweek 12 (p=0.01; Table 3). Therewere no signiﬁcant changes or dif-
ferences among groups in any other biomarkers which included TNF-α,
adiponectin, TGF-β, uric acid and FGF23. Changes in mGFR and eGFR at
12 weeks analyzed by the primary pre-speciﬁed subgroup of baseline
eGFR ≤30 or N30ml/min/1.73m2 are provided in the Supplemental Ap-
pendix, Figs. S1 and S2. There was a suggestion of a more pronounced
treatment effect in patients with a baseline eGFR N30 ml/min/1.73 m2:
within the subgroup with higher baseline eGFR, the eGFR change from
baseline at 12 weeks was signiﬁcantly different for the
rexlemestrocel-L 150 × 106 group compared to placebo ((p = 0.04);
Supplemental Fig. S2C).
The effects of a single infusion of rexlemestrocel-L or placebo on
eGFR change from baseline over the entire 60 week post-infusion
study period are shown in Fig. 3. Relative to placebo therewas a sugges-
tion of stabilization of eGFR in the rexlemestrocel-L 150 × 106 group,
most notably at the 12-week primary endpoint.
4. Discussion
Therapies that delay or prevent progression of diabetic nephropathy
to end stage renal failure would be of immense clinical and economic
value. Because of the ability of allogeneic mesenchymal lineage cells to
track to injured tissues (Togel & Westenfelder, 2011) and potentially
exert anti-inﬂammatory, immunomodulatory and other paracrine
Table 3
Renal and metabolic parameters at baseline and changes from baseline at week 12
endpoint.
Placebo
(N = 10)
Rexlemestrocel-L
150 × 106
(N = 10)
300 × 106
(N = 10)
Serum creatinine (mg/dl)a 1.95 ± 0.58 1.97 ± 0.58 2.03 ± 0.71
Change from baseline
(mg/dl)
0.064 ± 0.0912 0.003 ± 0.0917 0.047 ± 0.0888
n = 10 n = 10 n = 10
Creatinine clearance (ml/min) 46.4 ± 13.8 55.2 ± 24.1 54.0 ± 29.0
Change from baseline
(ml/min)
3.1 ± 8.89 6.5 ± 7.96 −8.6 ± 7.48
n = 8 n = 9 n = 9
Albumin-creatinine ratio
(mg/g)b
205.2 (270.80) 142.0 (176.60) 158.8 (359.10)
Change from baseline
(mg/g)
−9.6 (127.40) 21.0 (93.50) 18.0 (169.70)
n = 9 n = 10 n = 10
Protein-creatinine ratio
(mg/g)b
412.7 (317.00) 302.6 (347.60) 297.3 (350.00)
Change from baseline
(mg/g)
−7.55 (149.050) 1.15 (175.650) 13.95 (225.150)
n = 9 n = 10 n = 10
Cystatin-C (mg/l) 1.49 ± 0.561 1.61 ± 0.408 1.31 ± 0.450
Change from baseline (mg/l) 0.43 ± 0.131 0.30 ± 0.143 0.52 ± 0.128
n = 10 n = 9 n = 10
HbA1c (%) 6.75 ± 1.34 7.53 ± 1.21 7.92 ± 2.13
Change from baseline (%) −0.07 ± 0.240 −0.03 ± 0.218 −0.36 ± 0.216
n = 9 n = 10 n = 10
Triglycerides (mmol/l)b,c 1.45 (1.40) 2.05 (0.50) 1.80 (1.00)
Change from baseline
(mmol/l)
0.05 (0.60) 0.10 (0.50) 0.15 (0.45)
% Change from baseline (%) 6.32 (28.8) 5.44 (25.63) 10.53 (24.11)
n = 10 n = 10 n = 10
Systolic blood pressure
(mm Hg)
132.7 ± 14.85 135.0 ± 16.99 136.3 ± 20.41
Change from baseline
(mm Hg)
8.0 ± 5.50 6.3 ± 5.51 6.1 ± 5.40
n = 10 n = 10 n = 10
Diastolic blood pressure
(mm Hg)
68.1 ± 11.12 72.0 ± 11.24 74.7 ± 12.18
Change from baseline
(mm Hg)
4.2 ± 3.02 −2.6 ± 3.00 5.6 ± 2.98
n = 10 n = 10 n = 10
hs-CRP (mg/l)b 1.00 (0.60) 3.50 (2.20) 0.95 (3.90)
Change from baseline (mg/l) 1.00 (3.90) 7.85 (16.90) 0.30 (1.25)
n = 10 n = 9 n = 10
IL-6 (pg/ml)b 3.44 (1.90) 4.29 (2.30) 2.76 (2.00)
Change from baseline
(pg/ml)
2.47 (2.85) 1.39 (5.46) −0.15 (0.910)d
n = 10 n = 9 n = 10
TNF-α (pg/ml) 2.98 ± 0.64 3.13 ± 0.99 2.98 ± 1.55
Change from baseline
(pg/ml)
0.11 ± 0.19 0.34 ± 0.20 0.13 ± 0.18
n = 10 n = 9 n = 10
a Baseline values aremean± SD ormedian (IQR). Change frombaseline values are least
squaresmeans±SEobtained fromanANCOVAmodelwith treatment and screening eGFR
stratum (≤30 or N30 ml/min/1.73 m2) as factors, and baseline values as covariate.
b Values are median (IQR). Treatment differences estimated using Hodges-Lehmann
estimator and Moses method. Analysis by Cochran-Mantel-Haenszel test in a nonpara-
metric ANCOVA model with treatment as factor adjusting for screening eGFR stratum
and baseline value.
c Both change and percent change from baseline are shown for triglycerides.
d p= 0.01 versus Placebo.
Fig. 2.mGFR least squaresmean change (SE) frombaseline at 12weeks by group (A). eGFR
least squares mean change (SE) from baseline at 12 weeks by group (B). Values are least
squares mean ± SE derived from ANCOVA model using treatment and eGFR strata as
factors and baseline value as covariate.
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fects of these cells in vivo are likely to explain their clinical potential
(Psaltis et al., 2010; See et al., 2011) as there is little evidence of engraft-
ment of systemically administered cells (von Bahr et al., 2012).
This study represents the ﬁrst double-blind, placebo-controlled trial
of an allogeneic, bone-marrow derived mesenchymal lineage cell prod-
uct in patients with chronic kidney disease due to type 2 diabetes. The
study was designed to assess acute and chronic safety and immunolog-
ical sensitization potential following a single infusion of rexlemestrocel-
L. In addition, although the study was not powered for efﬁcacy, a
hypothesis-generating signal was observed with consistency between
isotopically measured and creatinine-based estimations of renal func-
tion at the prespeciﬁed primary endpoint 12 weeks post-infusion. The
12 week timepoint was selected as the primary exploratory endpoint
based on similar early phase clinical development studies in diabetic ne-
phropathy (Pergola et al., 2011; Ruilope et al., 2014) and a previous
study in subjects with type 2 diabetes that showed a trend for improved
glycemic control at 8 weeks which dissipated thereafter (Skyler et al.,
2015).
No observed changes in glycemic parameters (HbA1c, fasting plas-
ma glucose or insulin) were observed. While this study was conducted
in patients with nephropathy consequent to type 2 diabetes, the most
common cause of end-stage renal disease, the subjects in our study var-
ied widely with respect to degree of hyperglycemia (HbA1c range: 5.1%
to 11.2%) and concomitant diabetesmedications: 23.3%were on a back-
ground regimen of a single oral agent, most commonly sulfonylurea or
biguanide; 20% were on insulin; 20% were on multiple oral agents,
20% on insulin plus oral; and 17% were managed by diet alone. More-
over, per protocol, investigators were allowed to make any changes intype 2 diabetes therapy over the entire study period as deemed appro-
priate for individual patients.
The infusions were well-tolerated and the safety proﬁle we report is
comparable across all treatment groups. Theoretical risks of an alloge-
neic cell therapy including allergic risks due to excipients such as fetal
calf serum or immunogenic responses to human antigens (donor HLA)
were not observed. Cross matching between donor cells and recipient
was not performed prior to infusion. In addition, subjects were not
Fig. 3. eGFR least squaresmean change (SE) from baseline over 60week study by group. Values are least squaresmean± SEderived fromANCOVAmodel using treatment and eGFR strata
as factors and baseline value as covariate. MPC150M= rexlemestrocel-L 150 × 106; MPC300M= rexlemestrocel-L 300 × 106.
268 D.K. Packham et al. / EBioMedicine 12 (2016) 263–269excluded from participation based on assessment of antibodies to the
donor HLA. Importantly in this patient population, no patients devel-
oped sustained antibodies speciﬁc to thedonor HLAor showed clinically
relevant sustained increases in Class I or Class II %PRA, consistent with
the immune tolerant proﬁle of this cell type and a previous study show-
ing no evidence of rexlemestrocel-L induced antibodies or immune sys-
tem events (Skyler et al., 2015). These cells are negative for HLA Class II
and CD80 and CD86 co-immunostimulatory molecules, and exert po-
tential immunomodulatory effects including inhibition of T-cell prolif-
eration (Togel & Westenfelder, 2011). The observed lack of acute
immunological responses to unmatched allogeneic MPC is particularly
important in patients who may eventually require kidney transplanta-
tion. Possibly, repeated administration of this product may enhance
the observed modest signal of GFR preservation, relative to placebo.
Lack of any evidence of sustained sensitization and development of an-
tibodies speciﬁc to the donor HLA suggests that repeat administration of
this therapy may be a feasible option in this patient population. The de-
sign of future studies may include assessment of safety, tolerability and
efﬁcacy of single and repeated administration of the product.
There are limitations to our study. First, the sample size was too
small to demonstrate statistically signiﬁcant effects on renal function.
Moreover, the possibility of type 1 error cannot be excluded based on
multiple exploratory statistical analyses performedwithout adjustment
for multiplicity. In addition, the small sample size (N = 30) while ap-
propriate for a ﬁrst in human investigation cannot exclude rarer safety
events than would be detected over 60 weeks following a single infu-
sion. Second, the study duration (12 weeks) to assess acute effects of a
single administration with a 48 week follow-up is too brief to evaluate
a chronic disease with variable and frequently slow progression. Selec-
tion of patients with documented recent rapid progression of their
chronic kidney disease may more likely show treatment effects, partic-
ularly over a brief study duration. Third, thewide range of baseline albu-
minuria and proteinuria (ACR 21 to 3000 mg/g) as well as serum
biomarkers in a small number of patients complicated the assessment
of changes within and between groups in these parameters. Selection
of subjects within a narrow range of baseline proteinuria may provide
more useful information. With respect to serum biomarkers of inﬂam-
mation, owing to within subject variability as well as sensitivity of the
available assays, systemically measured inﬂammatory cytokines proba-
bly require substantially larger numbers of subjects per group to identi-
fy meaningful changes and treatment differences over time. Lastly,
repeated isotopically measured GFR assessments beyond 12 weeks to
conﬁrm eGFR ﬁndings were not performed because of radioisotope ex-
posure. Serum-creatinine based eGFR equations may underestimate or
overestimate GFR.In future studies, selection of patients with prognostic indicators of
rapid progression to end stage renal failure would support exploration
of a treatment paradigm whereby repeat infusions over a prolonged
time course are demonstrated to be tolerated and result in durable
and clinically meaningful responses. Repeat dosing, if demonstrated to
be safe and well-tolerated, may provide greater clinical efﬁcacy and
may be appropriate in assessing the long-term effects on renal function.
Although there were no immune related adverse events, we have not
reinfused subjects with cells from the same donor to conﬁrm lack of
sensitization.
In conclusion, the safety, apparent immune tolerance of allogene-
ic MPC and a potential efﬁcacy signal of rexlemestrocel-L relative to
placebo, and the medical need to develop new therapies to preserve
or enhance renal function in this population support further investi-
gation in diabetic nephropathy in appropriately sized and powered
studies of longer duration, including periodic dosing to assess the
durability of effect and optimal dose and frequency of repeat
administration.Funding Source
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